Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 22 for “"PBPK modelling"”.

  1. Physiologically based Pharmacokinetic (PBPK) Modelling of Cisplatin in Rats and Humans

    The physiologically based pharmacokinetic (PBPK) modelling has been accepted as one of the most effective mechanistic techniques to analyze pharmacokinetics (PK) of drugs in the drug development process. Its effectiveness in predicting the PK of drugs is important not only to the current drug …

    waterloo Repository record for Physiologically based Pharmacokinetic (PBPK) Modelling of Cisplatin in Rats and Humans (opens in a new tab)

  2. Theory and application of PBPK modelling in drug development: the double-edged sword of complexity

    Physiologically-based pharmacokinetic modelling has become an integral part of model-informed drug development. However, the extensive structure and parameterisation of such models may give rise to issues with model identifiability, parameter estimation and model analysis techniques. In this …

    oxford Repository record for Theory and application of PBPK modelling in drug development: the double-edged sword of complexity (opens in a new tab)

  3. An investigation into paediatric gastrointestinal physiology and its applications in in silico pbpk modelling for age-appropriate formulations

    … such as physiologically-based pharmacokinetic (PBPK) modelling and improve representability of paediatric subjects. This thesis specifically characterises (i) the abundance and ontogeny of paediatric intestinal drug metabolising enzymes and transporters (DMET) proteins and (ii) the amount of …

    birmingham Download PDF for An investigation into paediatric gastrointestinal physiology and its applications in in silico pbpk modelling for age-appropriate formulations (opens in a new tab)

  4. The application of mechanistic modelling as a tool in drug disposition and risk assessment

    … of drug development. Pharmacokinetic modelling approaches, such as physiologically-based pharmacokinetic (PBPK) modelling, can cater to most of the critical PK issues and at the same time optimise the utilising of resources. The overall aim of this work was to illustrate, explore and …

    aston Repository record for The application of mechanistic modelling as a tool in drug disposition and risk assessment (opens in a new tab) Download PDF for The application of mechanistic modelling as a tool in drug disposition and risk assessment (opens in a new tab)

  5. Physiologically Based Pharmacokinetic Modelling as a Tool for Dose Optimisation in Special Population Groups

    … of physiologically based pharmacokinetic (PBPK) modelling, an approach that predicts drug disposition by integrating physiological and drug parameters. The objective is to elucidate the impact of physiological alterations within special populations on drug pharmacokinetics, aiming to …

    aston Repository record for Physiologically Based Pharmacokinetic Modelling as a Tool for Dose Optimisation in Special Population Groups (opens in a new tab) Download PDF for Physiologically Based Pharmacokinetic Modelling as a Tool for Dose Optimisation in Special Population Groups (opens in a new tab)

  6. Physiologically based pharmacokinetic modelling of antimalarial agents

    … of physiologically based pharmacokinetic (PBPK) modelling in antimalarial drug research is evolving. Antimalarial agents are subject to drug-drug interactions (DDIs) and the resultant pharmacokinetics in special population groups is not well understood. To optimise antimalarial dosing in …

    aston Download PDF for Physiologically based pharmacokinetic modelling of antimalarial agents (opens in a new tab)

  7. Small-scale in vitro methods for evaluating the impact of gastrointestinal transfer on luminal drug / drug product performance in the fasted state

    … into physiologically based pharmacokinetic (PBPK) software and pharmacokinetic parameters estimated from simulated adult plasma profiles were compared with published values of pharmacokinetic parameters estimated from actual plasma data in healthy adults. Data from the biphasic dissolution …

    greece Repository record for Small-scale in vitro methods for evaluating the impact of gastrointestinal transfer on luminal drug / drug product performance in the fasted state (opens in a new tab)

  8. The importance of measured rat tissue partition coefficients in physiological based pharmacokinetic modelling : and the impact on human translational strategies in early drug discovery

    Physiologically based pharmacokinetic (PBPK) modelling is an established in silico platform for simulating pharmacokinetics in pre-clinical species and humans, and is widely used within drug metabolism and pharmacokinetics (DMPK) research to facilitate the design of drug molecules with human …

    strathclyde Repository record for The importance of measured rat tissue partition coefficients in physiological based pharmacokinetic modelling : and the impact on human translational strategies in early drug discovery (opens in a new tab)

  9. Mother matters - Advancing HIV therapy in pregnancy and lactation

    … and women living with HIV, supplemented by PBPK modelling to predict concentrations in breastmilk. The observed and predicted concentrations were generally low and suggest no clinically relevant toxicity to infants. In addition, factors influencing the implementation of guideline changes …

    radboud Repository record for Mother matters - Advancing HIV therapy in pregnancy and lactation (opens in a new tab)

  10. Advancing chemical risk assessment through in silico new approach methodologies (NAMs): a quantitative adverse outcome network (qAON) framework linking perfluorooctanoic acid (PFOA) exposure to cardiovascular disease (CVD)-relevant mechanisms

    … atmospheric dispersion and multimedia fate modelling, probabilistic exposure reconstruction, physiologically based pharmacokinetic (PBPK) modelling, human biomonitoring, liver transcriptomics, survey-weighted NHANES analysis, adverse outcome pathway (AOP) development, quantitative in …

    greece Repository record for Advancing chemical risk assessment through in silico new approach methodologies (NAMs): a quantitative adverse outcome network (qAON) framework linking perfluorooctanoic acid (PFOA) exposure to cardiovascular disease (CVD)-relevant mechanisms (opens in a new tab)

  11. Development towards prospective modelling of in vivo rabbit QTc prolongation

    … ex vivo, in vivo) conducted and integrated using modelling/scaling approaches to develop compartmental and physiologically based models from early cardiovascular screening and pharmacokinetic data to predict measured in vivo rabbit QTc PKPD data. A terminally anaesthetised rabbit model was set-up …

    strathclyde Repository record for Development towards prospective modelling of in vivo rabbit QTc prolongation (opens in a new tab)

  12. Use of Physiologically-Based Pharmacokinetic Modelling To Support Dose Optimization in The Critically Ill

    … physiologically-based pharmacokinetic (PBPK) modelling are encouraging to overcome some of the current challenges and knowledge gaps towards optimizing drug therapy in critically ill patients. PBPK models leverage mechanistic principles to incorporate knowledge of physiology and drug …

    waterloo Repository record for Use of Physiologically-Based Pharmacokinetic Modelling To Support Dose Optimization in The Critically Ill (opens in a new tab)

  13. Evaluation of prophylactic cefuroxime dose in obese pregnant women undergoing caesarean section

    … and (4) A physiologically based pharmacokinetic (PBPK) obese–pregnant model was utilised to predict cefazolin and cefuroxime disposition in such population. At around 1–1.5 hours post cefuroxime 1500 mg dose, reported clinical cefuroxime plasma concentrations ranged within 8.7–57 mg/L in …

    birmingham Download PDF for Evaluation of prophylactic cefuroxime dose in obese pregnant women undergoing caesarean section (opens in a new tab)

  14. Development of Novel Excipient Screening Platform for Paediatric Oral Formulations

    … for the first time, an attempt to integrate PBPK modelling to a paediatric specific formulation development approach to clinically inform an appropriate dosage form design and strategy was made. A 5 mg sustained release mini-tablet was successfully developed, with duration of release …

    aston Repository record for Development of Novel Excipient Screening Platform for Paediatric Oral Formulations (opens in a new tab) Download PDF for Development of Novel Excipient Screening Platform for Paediatric Oral Formulations (opens in a new tab)

  15. Current Challenges for the Development of Inhaled Medicines

    … overestimation of particle sizes to improve modelling predictions due to constraints on diffusion, identifying a need to integrate in vitro dissolution methods with mechanistic models that account for pulmonary kinetics. Nor did the modelling account for reversible esterification, identifying …

    kings Repository record for Current Challenges for the Development of Inhaled Medicines (opens in a new tab) Download PDF for Current Challenges for the Development of Inhaled Medicines (opens in a new tab)

  16. In vitro and in silico profiling to assist pharmaceutical development

    … of physiologically based pharmacokinetic modelling provides a potential solution by making use of the physico-chemical information along with the human physiology to simulate the clinical performance.;In this work an experimental approach is presented to study the in vitro solubility of …

    strathclyde Repository record for In vitro and in silico profiling to assist pharmaceutical development (opens in a new tab)

  17. Optimising Therapeutic Outcomes in CNS Disorders: Pharmaceutical and Pharmacokinetic Approaches

    … of a phytochemical and the use of in-silico modelling to optimise antidepressant dosing in challenging populations such as pregnant women. The flavonoid hesperetin, as a potential candidate for CNS disorders, was incorporated into commercial base creams (Vanish-Pen™, Doublebase™ gel, …

    aston Download PDF for Optimising Therapeutic Outcomes in CNS Disorders: Pharmaceutical and Pharmacokinetic Approaches (opens in a new tab)

Page 1 of 2